Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Gasparotto, Juciano ^a   Ribeiro, Camila Tiefensee ^a   Bortolin, Rafael Calixto ^a   Somensi, Nauana ^a   Rabelo, Thallita Kelly ^a   Kunzler, Alice ^a   Souza, Natália Cabral ^b   Pasquali, Matheus Augusto De Bittencourt ^c   Moreira, José Claudio Fonseca ^a   Gelain, Daniel Pens ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c FEDERAL UNIVERSITY OF CAMPINA GRANDE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AUTACOID; CYTOKINE; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXIDOPAMINE; PROTEIN TYROSINE KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; MALE; METABOLISM; PARKINSON DISEASE; PATHOLOGY; RAT; SUBSTANTIA NIGRA;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; INFLAMMATION MEDIATORS; MALE; NF-KAPPA B; OXIDOPAMINE; PARKINSON DISEASE; RATS; RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS; SRC-FAMILY KINASES; SUBSTANTIA NIGRA;

EID: 85027843681     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-09257-3     Document Type: Article

References (34)

1. Wang, Q., Liu, Y. & Zhou, J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener 4, doi:10.1186/s40035-015-0042-0 (2015).
2. Juranek, J. K. et al. Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis. Front Cell Neurosci 9, doi:10.3389/fncel.2015.00485 (2015).
3. Deane, R. et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122, 1377-1392, doi:10.1172/jci58642 (2012).
4. Teismann, P. et al. Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiology of aging 33, 2478-2490, doi:10.1016/j.neurobiolaging.2011.12.006 (2012).
5. De Jesus-Cortes, H. et al. Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease. NPJ Parkinsons Dis 1, doi:10.1038/npjparkd.2015.10 (2015).
6. Thiele, S. L., Warre, R. & Nash, J. E. Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease. J Vis Exp. doi:10.3791/3234 (2012).
7. Hong, Y. et al. Effects of RAGE-Specific Inhibitor FPS-ZM1 on Amyloid-beta Metabolism and AGEs-Induced Inflammation and Oxidative Stress in Rat Hippocampus. Neurochem Res 41, 1192-1199, doi:10.1007/s11064-015-1814-8 (2016).
8. Yang, F. et al. Receptor for advanced glycation end-product antagonist reduces blood-brain barrier damage after intracerebral hemorrhage. Stroke 46, 1328-1336, doi:10.1161/strokeaha.114.008336 (2015).
9. Maczurek, A., Shanmugam, K. & Munch, G. Inflammation and the redox-sensitive AGE-RAGE pathway as a therapeutic target in Alzheimer's disease. Annals of the New York Academy of Sciences 1126, 147-151, doi:10.1196/annals.1433.026 (2008).
10. Xie, J., Mendez, J. D., Mendez-Valenzuela, V. & Aguilar-Hernandez, M. M. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cellular signalling 25, 2185-2197, doi:10.1016/j.cellsig.2013.06.013 (2013).
11. Tobon-Velasco, J. C., Cuevas, E. & Torres-Ramos, M. A. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS & neurological disorders drug targets 13, 1615-1626 (2014).
12. Dunkley, P. R., Bobrovskaya, L., Graham, M. E., von Nagy-Felsobuki, E. I. & Dickson, P. W. Tyrosine hydroxylase phosphorylation: regulation and consequences. Journal of neurochemistry 91, 1025-1043, doi:10.1111/j.1471-4159.2004.02797.x (2004)
13. Grealish, S., Mattsson, B., Draxler, P. & Bjorklund, A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci 31, 2266-2278, doi:10.1111/j.1460-9568.2010.07265.x (2010).
14. Simola, N., Morelli, M. & Carta, A. R. The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 11, 151-167 (2007).
15. Dauer, W. & Przedborski, S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
16. Zhang, H. et al. Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury. Cell death & disease 5, e1288, doi:10.1038/cddis.2014.248 (2014).
17. Ray, R., Juranek, J. K. & Rai, V. RAGE axis in neuroinflammation, neurodegeneration and its emerging role in the pathogenesis of amyotrophic lateral sclerosis. Neuroscience and biobehavioral reviews 62, 48-55, doi:10.1016/j.neubiorev.2015.12.006 (2016).
18. Safavi-Abbasi, S., Wolff, J. R. & Missler, M. Rapid morphological changes in astrocytes are accompanied by redistribution but not by quantitative changes of cytoskeletal proteins. Glia 36, 102-115 (2001).
19. Avignone, E., Lepleux, M., Angibaud, J. & Nägerl, U. V. Altered morphological dynamics of activated microglia after induction of status epilepticus. J Neuroinflammation 12, doi:10.1186/s12974-015-0421-6 (2015).
20. Healy-Stoffel, M., Ahmad, S. O. & Stanford, J. A. & Levant, B. Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats. Neurosci Lett 546, 26-30, doi:10.1016/j.neulet.2013.04.033 (2013).
21. Ramasamy, R. et al. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15, 16r-28r, doi:10.1093/glycob/cwi053 (2005).
22. Li, J. & Schmidt, A. M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. The Journal of biological chemistry 272, 16498-16506 (1997).
23. Ishihara, K., Tsutsumi, K., Kawane, S., Nakajima, M. & Kasaoka, T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS letters 550, 107-113 (2003).
24. Sathe, K. et al. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-alpha pathway. Brain: a journal of neurology 135, 3336-3347, doi:10.1093/brain/aws250 (2012).
25. Santoro, M. et al. In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. Neurobiol Dis 91, 59-68, doi:10.1016/j. nbd.2016.02.018 (2016).
26. Santiago, R. M. et al. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Progress in neuro-psychopharmacology & biological psychiatry 34, 1104-1114, doi:10.1016/j.pnpbp.2010.06.004 (2010).
27. National Institutes of Health Guide for Careand Use of Laboratory Animals. Eighth Edition. Avaiable in https://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-Use-of-Laboratory-Animals.pdf Accessed 15 Jan 2017 (1985).
28. Lima, M. M. et al. Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies. CNS & neurological disorders drug targets 11, 439-449 (2012).
29. Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates. Sixth edition. Academic Press (2007).
30. Gasparotto, J. et al. Increased tau phosphorylation and receptor for advanced glycation endproducts (RAGE) in the brain of mice infected with Leishmania amazonensis. Brain Behav Immun 43, 37-45, doi:10.1016/j.bbi.2014.06.204 (2015).
31. Colle, D. et al. Probucol Increases Striatal Glutathione Peroxidase Activity and Protects against 3-Nitropropionic Acid-Induced Pro-Oxidative Damage in Rats. PLoS One 8, doi:10.1371/journal.pone.0067658 (2013).
32. Boix, J., Padel, T. & Paul, G. A partial lesion model of Parkinson's disease in mice-characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behav Brain Res 284, 196-206, doi:10.1016/j.bbr.2015.01.053 (2015).
33. Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L. & Bland, S. T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777-787 (2000).
34. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254 (1976).